Advertisement

Mycopathologia

, Volume 172, Issue 3, pp 227–232 | Cite as

Disseminated Cryptococcosis in a Non-Hodgkin’s Lymphoma Patient with Late-Onset Neutropenia Following Rituximab-CHOP Chemotherapy: A Case Report and Literature Review

  • Yuji Hirai
  • Yusuke Ainoda
  • Takayo Shoji
  • Takahiro Fujita
  • Kentaro Yoshinaga
  • Masayuki Shiseki
  • Naoki Mori
  • Masanao Teramura
  • Kyoichi Totsuka
  • Toshiko Motoji
Article

Abstract

Rituximab-related late-onset neutropenia (R-LON) is an adverse event associated with rituximab. A 65-year-old woman presented with diffuse large B-cell lymphoma of the kidney without bone marrow involvement. She was treated with 4 cycles of CHOP chemotherapy consisting of doxorubicin, cyclophosphamide, vincristine, and prednisolone at 4-week intervals. Rituximab was also administrated of the second, third, fourth CHOP cycles. She developed a high fever of 38°C, nausea, and severe neutropenia following the four cycles of R-CHOP chemotherapy. Her leukocyte count was 160/μl without neutrophils. Initially, a blood and pleural fluid and cerebrospinal fluid cultures were positive for Cryptococcus neoformans. Once she became asymptomatic following treatment with fluconazole and neutropenia was recovered with lenograstim, she had neck stiffness and admitted soon. Cerebro-spinal fluid (CSF) culture was positive for Cryptococcus neoformans. Treatment with amphotericin B(AMPH-B) and flucytosine(5-FC) was initiated as diagnosis of cryptococcus meningitis. Lenograstim was administrated for 9 months, and amount of dose was 9,750 μg. Cryptococcosis with malignant lymphoma is rare disease, and previously 17 cases were reported. Of note, mortality of disseminated cryptococcosis with malignant lymphoma is 54%. The more and more rituximab is widely used; the cases of severe infection in R-LON may increase.

Keywords

Rituximab Neutropenia Late onset Cryptococcosis Malignant lymphoma 

Notes

Conflicts of interest

None.

References

  1. 1.
    Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Voog E, Morschhauser F, Solal-Céligny P. Neutropenia in patients treated with Rituximab. N Eng J Med. 2003;348(26):2691–4.CrossRefGoogle Scholar
  3. 3.
    Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J. Hägglund H. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol. 2008;25:374–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Hematol. 2003;121:913–8.CrossRefGoogle Scholar
  5. 5.
    Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A, Takahashi K, Oshima K, Kanda Y, Chiba S, Motokura T, Kurokawa M. A high incidence of late-onset neutropenia following rituzimab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol. 2007;18(2):364–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F, Alhusein Q, Antal D, Salles G, Coiffier B. Non-Hodgkin’s lymphoma Rituximab-related late-onset neutropenia autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33:921–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Hirayama Y, Kohda K, Konuma Y, Hirata Y, Kuroda H, Fujimi Y, Shirao S, Kobune M, Takimoto R, Matsunaga T, Kato J. Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantaion with rituximab. Intern Med. 2009;48:57–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol. 2009;84(7):414–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Fukuno K, Tsurumi H, Ando N, Kanemura N, Goto H, Tanabashi S, Okamoto K, Moriwaki H. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin’s lymphoma. Int J Hematol. 2006;84:242–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, Barista I. Rituximab-related viral infections in lymphoma patients. Leuk Lymphom. 2007;48(7):1307–12.CrossRefGoogle Scholar
  11. 11.
    Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy-rare but there!. Leuk Lymphom. 2009;50(7):1083–95.CrossRefGoogle Scholar
  12. 12.
    Cornely OA, Heidecke CN, Karthaus M. Opportunistic infections (OI) following monoclonal antibody treatment. J Clin Oncol. 2005;23(16S):2562. (From the 2005 ASCO Annual Meeting).Google Scholar
  13. 13.
    Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilberg O. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009;101(4):248–55.PubMedCrossRefGoogle Scholar
  14. 14.
    Aksoy S, Dizdar O, Hayran M, Harputluoğlu H. Infections complications of rituximab in patients with lymphoma during maintenance therapy : a systematic review and meta analysis. Leuk Lymphom. 2009;50(3):357–65.CrossRefGoogle Scholar
  15. 15.
    Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy. Cancer. 2007;109(11):2182–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Lin PC, Hsiao LT, Poh SB, Wang WS, Yen CC, Chao TC, Liu JH, Chiou TJ, Chen PM. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Ann Hematol. 2007;86:95–100.PubMedCrossRefGoogle Scholar
  17. 17.
    Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious disease society of America. Clin Infect Dis. 2010;50(3):291–322.PubMedCrossRefGoogle Scholar
  18. 18.
    Muñoz P, Giannella M, Valerio M, Soria T, Díaz F, Longo JL, Bouza E. Cryptococcal meningitis in a patient treated with infliximab. Diagn Microbiol Infect Dis. 2007;57:433–46.CrossRefGoogle Scholar
  19. 19.
    Korfel A, Menssen HD, Schwartz S, Thiel E. Cryptococcus in Hodgkin’s disease: description of two cases and review of the literature. Ann Hematol. 1998;76:283–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Escudier E, Cordonnier C, Poirier J. Infections of the central nervous system in malignant hemopathies. Rev Neurol. 1986;142(2):116–25. (French)Google Scholar
  21. 21.
    Dinçol G, Kahraman R. Cryptococcus neoformans meningitis in a patient with hairy cell Leukmia. Am J Hematol. 2006;81:387.Google Scholar
  22. 22.
    Reisfeld-Zadok S, Elis A, Szyper-Kravitz M, Chowers M, Lishner M. Cryptococcal meningitis in chronic lymphocytic leukemia patients. Isr Med Assoc J. 2009;11:437–9.PubMedGoogle Scholar
  23. 23.
    Rhew DC, Gaultier CR, Daar ES, Zakowski PC, Said J. Infections in patients with chronic adult T-cell leukemia/lymphoma: case report and review. Clin Infect Dis. 1995;21:1014–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Sánchez-Ojanguren J, Isern-Segura I, Chico-Chumillas C, Javaloyas-de-Morlius M. Cryptococcus neoformans meningoencephalitis in a patient treated with rituximab. Med Clin. 2009;133(4):157–8. (Spanish)Google Scholar
  25. 25.
    Vigouroux S, Morin O, Milpied N, Mahé B, Rapp MJ, Harousseau JL. Cryptococcus neoformans infection in hematologic malignancies. Rev Med Interne. 2000;21:955–60. (French)Google Scholar
  26. 26.
    Finke R, Strobel ES, Kroepelin T, Guzman J, Klein PJ, Schaefer HE, Kappe R, Müller J. Disseminated cryptococcosis in a patient with malignant lymphoma. Mycoses. 1988;31(1):102–8.Google Scholar
  27. 27.
    Eric Searls D, Sico JJ, Bulent Omay S, Bannykh S, Kuohung V, Baehring J. Unusual presentations of nervous system infection by Cryptococcus neoformans. Clin Neuro Nurosurg. 2009;111:638–42.CrossRefGoogle Scholar
  28. 28.
    Romano C, Taddeucci P, Donati D, Miracco C, Massai L. Primary cutaneous cryptococcosis due to Cryptococcus neoformans in a woman with non-Hodgkin’s lymphoma. Acta Derm Venereol. 2001;81(3):220–1.PubMedCrossRefGoogle Scholar
  29. 29.
    Sánchez A, Cantos B, España P, Salas C, Provencio M. Hodgkin’s disease and intercurrent processes that may simulate a relapse. Clin Transl Oncol. 2008;10(7):439–41.PubMedCrossRefGoogle Scholar
  30. 30.
    Fujita Y, Kasahara K, Uno K, Konishi M, Maeda K, Yoshimoto E, Murakawa K, Mikasa K, Amano I, Morii T, Kimura H. Amphotericin B-induced nephrogenic diabetes insipidus in a case of cryptococcemia. Intern Med. 2005;44(5):458–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Bolignano G, Chindemi G, Criseo G. Cryptococcal meningoencephalitis in a patient with Hodgkin’s lymphoma: successful treatment with fluconazole. Mycoses. 1991;34(1–2):63–5.PubMedGoogle Scholar
  32. 32.
    Amthor M, Arents B, Bartelheimer E. Cryptococcal sepsis simulating miliary tuberculosis in malignant lymphoma. Pneumologie 1991;45(3):110–3. (German)Google Scholar
  33. 33.
    Sharma M, Khatib R, Jones BA, Fakih MG. Cryptococcus neoformans myositis without dissemination. Scand J Infect Dis. 2002;34(11):858–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Okawa Y, Shimada T, Nagasaki E, Nozato A, Mizoroki F, Kobayashi M. Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma. Rinsho Ketsueki. 2006;47(7):650–5. (Japanese)Google Scholar
  35. 35.
    Nowicka J, Mazur G, Kuliczkowski K, Gola A, Kochman A, Baran E, Walów B. Cryptococcal infection and lymphogranulomatous infiltration of the central nervous system in Hodgkin’s disease. Mycoses. 1994;37:439–41.PubMedCrossRefGoogle Scholar
  36. 36.
    Rajkumar K, Rajkumar T, Sagar TG, Maitreyan V, Shanta V. Cryptococcal Meningitis in a patient with Hodgkin’s Lymphoma. J Assoc Physicians India. 1992;40(10):707–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Yuji Hirai
    • 1
    • 2
  • Yusuke Ainoda
    • 1
  • Takayo Shoji
    • 1
  • Takahiro Fujita
    • 1
  • Kentaro Yoshinaga
    • 2
  • Masayuki Shiseki
    • 2
  • Naoki Mori
    • 2
  • Masanao Teramura
    • 2
  • Kyoichi Totsuka
    • 1
  • Toshiko Motoji
    • 2
  1. 1.Department of Infectious DiseaseTokyo Women’s Medical UniversityTokyoJapan
  2. 2.Department of HematologyTokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations